Capricor Weighs Cost Cuts After Second FDA Rejection of Deramiocel
CAPR is trading near its 52-week low of $2.96 (44% below the low) on elevated volume (4.3× avg).
Summary
The FDA issued a Complete Response Letter rejecting Deramiocel for Duchenne muscular dystrophy, saying the data do not establish substantial evidence of effectiveness and citing other clinical deficiencies. This is the second CRL for the lead asset in less than two years, following the July 2025 rejection, and an FDA advisory panel had already voted against recommending approval. Shares fell more than 78% in post-market trading Friday. Capricor says it held $198.5 million in cash and securities at Sept. 30, enough for 12 months, but is now reviewing operating expenses to stretch that runway — a signal the program's economics are being reworked. With the lead asset effectively blocked and cash burn running at a $42.7 million quarterly loss, the thesis shifts to pipeline salvage and financing risk.
At the time of this announcement, CAPR was trading at $1.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $441.3M. The 52-week trading range was $2.96 to $40.37. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.